COSTA MESA, Calif., Dec. 22, 2014 /PRNewswire-iReach/ -- WCCT Global is known as a CRO that meets or exceeds its recruitment commitments in the conduct of clinical trials in early and late phase research. Again, WCCTG is pleased to report today that they were the largest contributor of patients by over twice as much as the next highest contributor in a competitive phase I clinical trial. The study required a total of 350 patients from 8 sites. WCCT Global was able to enroll, retain and complete 155 patients and the next closest competitor enrolled 74. This is a significant achievement that once again demonstrated the effectiveness of WCCT Global’s patient recruitment division called “In-Site” and its ability to recruit large numbers of quality patients for clinical research. The patient recruitment division has multiple recruitment strategies; all are focused on notifying patients about the trial and keeping the volunteers engaged throughout the entire screening and in-life study process. The recruitment success reported today is another validation of the WCCT Global’s In-Site recruitment tool. WCCT Global’s phase I clinical pharmacology unit is located in Cypress, California and has over 150 beds for overnight stays. The CPU’s location is ideal for phase I trials because it is easily accessible and in a densely populated part of Orange County, California.
Photo - http://photos.prnewswire.com/prnh/20141220/165694LOGO
Ed Kim, WCCT Global’s Executive Director, Early Clinical Development stated, " Our phase I unit is designed to run the most efficient phase I trial possible and with that comes the ability to screen an extremely large number of patients needed to enroll a trial on time and ahead of the competition. At WCCT, we pride ourselves in being a leader in phase I development.”
More about WCCT Global:
WCCT Global is a multi-site, full-service global contract research organization (CRO) of outsourced early drug development and late phase services to the pharmaceutical, biotechnology and medical device industries. The WCCT Global vision, “With compassion for people, we strive for tomorrow’s therapies to be available today” truly exemplifies the focus and reason for our cutting-edge work both in our clinics and throughout our operations. As a drug development partner, WCCT Global collaborates with domestic and foreign innovator companies who need regulatory program management, data management and strategic consulting support, with an emphasis on overseeing and executing trials in special disease populations, pediatric populations, ethno-bridging, and cardiac safety. WCCT has extensive experience with healthy volunteer studies including First-in-Human (FIH), as well as specific therapeutic expertise in Allergy, Asthma, HCV, Ophthalmology, Oncology, Renal, and Vaccines.
To request more information about WCCT Global’s phase I capabilites and patient recruitment process, CLICK HERE
Media Contact:Matt Miller, WCCT Global, 714.668.1500 ext.2029, Matt.Miller@wcct.com
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE WCCT Global
Help employers find you! Check out all the jobs and post your resume.
